Familial Combined Hyperlipidemia: Myth or Reality?

Identificador:  imarina:9452253

Handle: https://hdl.handle.net/20.500.11797/imarina9452253

Autors:  Brouwers, M C G J; Klop, B; Ribalta, J; Cabezas, M Castro

Resum:
Purpose of ReviewFamilial combined hyperlipidemia (FCHL) was first described by Goldstein and co-workers in 1973 as a multiple-type hyperlipidemia in pedigrees with premature myocardial infarction. However, it can be questioned what actually defines FCHL.Recent FindingsAlthough initially regarded as an autosomal dominant disorder, quantitative trait linkage analyses have revealed multiple genes that are associated with the FCHL phenotype. With the advent of genome-wide association studies and next generation sequencing it has been confirmed that FCHL is a polygenic disorder and the associated gene variants, mostly with a triglyceride-raising effect, are not unique to FCHL. Furthermore, epidemiological studies have demonstrated that the multiple-type hyperlipidemia is also not specifically confined to FCHL.SummaryThis review provides a historical overview of the metabolic and genetic abnormalities that characterize FCHL. Integration of these findings with recent population-based, genetic studies results in a new pathophysiological concept of FCHL. This model provides practical guidance on how to approach an individual patient with an 'FCHL phenotype'.